-
Grace Therapeutics NasdaqCM:GRCE Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Location: 103 Carnegie Center, Princeton, NJ, 08540, United States | Website: https://www.gracetx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
18.38M
Cash
11.06M
Avg Qtr Burn
-3.51M
Short % of Float
0.27%
Insider Ownership
38.39%
Institutional Own.
39.75%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
GTx-104 Details Aneurysmal subarachnoid hemorrhage (aSAH) | NDA Submission | |
GTx-102 Details Ataxia-Telangiectasia | Phase 1 Update |